Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Urology · Prostate Cancer

Can Testosterone or Supplements Worsen Prostate Cancer?

At a Glance

Testosterone may stimulate active or advanced prostate cancer and oppose androgen deprivation therapy, so TRT and over-the-counter boosters require oncology guidance. After successful treatment, selected patients may consider TRT with shared decisions and close PSA monitoring.

If you are wondering whether prescription testosterone replacement therapy (TRT) or over-the-counter supplements will worsen your prostate cancer, the short answer is: it depends heavily on the stage and status of your cancer. There is no clear evidence that having normal testosterone levels causes prostate cancer in healthy men [1] [2]. However, for men with active, advanced, or high-risk prostate cancer, adding testosterone can stimulate cancer growth and is generally considered unsafe [3] [4]. For men who have been successfully treated for low-risk cancer, TRT may be a highly individualized option, but it requires strict specialist supervision [5].

Diagnosing True Testosterone Deficiency

Symptoms like fatigue, low mood, and low libido are common after prostate cancer diagnosis and treatment. However, these symptoms can also result from poor sleep, anemia, stress, or other medications. Before considering TRT, your doctor will need to confirm a true deficiency. This generally requires consistently low testosterone levels drawn from morning blood tests, alongside a physical evaluation to rule out other reversible causes [5]. Treating low testosterone based solely on symptoms without blood confirmation is not recommended.

Understanding Androgens and the “Saturation” Hypothesis

Prostate cells rely on androgens (male hormones like testosterone) to grow. Inside the body, testosterone is converted into a highly active form called DHT, which binds to androgen receptors inside prostate cells [6].

For a long time, it was assumed that adding any testosterone would automatically accelerate prostate cancer. Today, a biological hypothesis known as the saturation model offers a different perspective. This model proposes that androgen receptors can only absorb a certain amount of testosterone. Once these receptors are fully occupied (or “saturated”) at relatively low testosterone levels, adding more does not necessarily cause additional prostate growth [6].

While this model helps explain some observations in benign prostate tissue, it is not a guarantee of safety for cancer patients. Prostate tumors are highly adaptable. Some cancers can mutate to become hypersensitive to tiny amounts of testosterone, and others can even manufacture their own androgens to survive [7] [8]. Because of this biological unpredictability, the saturation model cannot be used to prove that extra testosterone is universally safe [9].

TRT and Your Cancer Status

The safety of using prescription TRT depends entirely on where you are in your cancer journey.

Cancer Status General Approach to TRT What the Evidence Says
Active, Advanced, or on ADT Generally Avoided TRT can stimulate cancer growth. It directly opposes Androgen Deprivation Therapy (ADT) and is usually contraindicated outside clinical trials [3] [4].
Active Surveillance Highly Cautionary Small observational studies suggest no immediate progression in carefully selected men with very low-risk disease, but long-term safety is unknown [10] [11]. Routine TRT is usually avoided [12].
Post-Prostatectomy (Surgery) Individualized / Shared Decision Observational data do not show increased recurrence in selected men if PSA remains undetectable [13] [14]. Strict monitoring is still required [5].
Post-Radiation Individualized / Shared Decision PSA remains detectable and can fluctuate after radiation. If the PSA trend remains stable over time, TRT might be considered, but evidence is limited [15] [16].
  • If you are on Androgen Deprivation Therapy (ADT): The primary goal of ADT is to starve prostate cancer cells of testosterone. Taking TRT or testosterone boosters will directly counteract your cancer treatment [17]. Never start TRT or an over-the-counter booster without your oncology team’s explicit direction.
  • A Note on PSA Monitoring: If you and your doctor decide to cautiously proceed with TRT after successful treatment, your PSA (Prostate-Specific Antigen) will be closely monitored. What constitutes a “safe” PSA depends on your treatment: after surgery, PSA is expected to be undetectable; after radiation, prostate tissue remains, so PSA may still be detectable but should stay at a stable, low level (a nadir) [15] [18].

The Truth About Over-the-Counter Supplements

Many over-the-counter (OTC) products are marketed as “testosterone boosters,” featuring ingredients like fenugreek, Tribulus, or zinc. There is no reliable clinical evidence that these supplements meaningfully or safely raise testosterone levels to treat a deficiency [19] [20].

More importantly, OTC supplements are not rigorously regulated for safety or effectiveness like prescription drugs. Studies have found that they can be contaminated with unauthorized synthetic compounds, heavy metals, or undisclosed hormone-active ingredients [21]. Because their exact effects are unknown, they pose a potential safety risk to anyone with a history of prostate cancer. Always bring the exact bottles or ingredient lists of any supplements you take to your oncology team for review.

Common questions in this guide

Can testosterone therapy make active prostate cancer grow faster?
Possibly. In men with active, advanced, or high-risk prostate cancer, added testosterone may stimulate cancer growth, so testosterone replacement therapy (TRT) is generally avoided. TRT also directly works against androgen deprivation therapy (ADT), which lowers testosterone to treat prostate cancer.
Can I use TRT after prostate cancer surgery or radiation?
Some carefully selected men may consider testosterone replacement after prostate cancer treatment, but it is not automatically safe. After surgery to remove the prostate, doctors generally look for an undetectable PSA; after radiation, they look for a stable, low PSA over time. The decision requires specialist discussion and close monitoring.
Are over-the-counter testosterone boosters safe with prostate cancer?
No reliable clinical evidence shows that over-the-counter testosterone boosters safely raise testosterone enough to treat a deficiency. They may contain undisclosed hormones, unauthorized drugs, or heavy metals because supplements are not regulated like prescription medicines. Show the exact product and ingredient list to your oncology team before taking it.
How do doctors confirm low testosterone before prescribing TRT?
Symptoms such as fatigue or low libido are not enough by themselves. Doctors usually confirm testosterone deficiency with consistently low testosterone levels from morning blood tests and a physical evaluation, while checking for other causes such as poor sleep, anemia, stress, or medication effects. Repeat testing may be needed.
Does the saturation model mean testosterone is safe for prostate cancer?
No. The saturation model suggests that prostate hormone receptors may become fully occupied at relatively low testosterone levels, but it does not prove that extra testosterone is safe in cancer. Some tumors can become more sensitive to small amounts of testosterone or make their own androgens.
What PSA level is considered safe while using TRT after prostate cancer?
There is no single PSA level that is safe for everyone using TRT after prostate cancer. After surgery to remove the prostate, PSA is generally expected to be undetectable; after radiation, some PSA may remain because prostate tissue is still present, but it should stay low and stable. Your cancer treatment history and PSA trend need to be interpreted by your oncology team.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

What Do PI-RADS 3, 4, and 5 Mean on a Prostate MRI? What to Do After a Negative Prostate Biopsy With High PSA? How Long Is ADT With Radiation for Prostate Cancer? What Is the Next Step After a High PSA? Testing Path When Is PSMA PET/CT Needed for Prostate Cancer Staging?
Show more
How Are the Six Prostate Cancer Risk Groups Defined? Can Prostatitis, BPH, Sex, or Cycling Raise PSA Levels? Can You Have Prostate Cancer With a Negative MRI, High PSA? How Do Cribriform and IDC-P Affect Prostate Cancer Risk? Surgery or Radiation Better for High-Risk Prostate Cancer? How Often Is Low-Risk Prostate Cancer Actively Monitored? Can a Second Review Change Your Prostate Cancer Grade? What Do T, N, and M Stages Mean in Prostate Cancer? Should I Get Genetic Testing After Prostate Cancer? How Do Age and Health Affect Prostate Cancer Treatment? When to Leave Active Surveillance for Prostate Cancer? Are Genomic Tests Useful for Prostate Cancer Decisions? Why Are Prostate Biopsies Done? Risks and Methods Explained When Should I Start Prostate Cancer Screening If High Risk?

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my Grade Group/Gleason score and current stage, and how do they affect the safety of testosterone treatments?
  2. 2.Has my PSA reached the expected nadir (lowest point) based on my specific prostate cancer treatment?
  3. 3.What is my current morning testosterone level, and do we need to check it again to confirm a deficiency?
  4. 4.Am I on any medications, such as Androgen Deprivation Therapy (ADT), that testosterone would directly oppose?
  5. 5.What non-hormonal options exist to help manage my fatigue, low libido, sleep issues, or mood changes?

References

References (21)
  1. 1

    Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.

    Michaud JE, Billups KL, Partin AW

    Therapeutic advances in urology 2015; (7(6)):378-87 doi:10.1177/1756287215597633.

    PMID: 26622322
  2. 2

    Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.

    Bhasin S, Travison TG, Pencina KM, et al.

    JAMA network open 2023; (6(12)):e2348692 doi:10.1001/jamanetworkopen.2023.48692.

    PMID: 38150256
  3. 3

    Testosterone Replacement Therapy in Men with Untreated or Treated Prostate Cancer: Do We Have Enough Evidences?

    Kim M, Byun SS, Hong SK

    The world journal of men's health 2021; (39(4)):705-723 doi:10.5534/wjmh.190158.

    PMID: 32648377
  4. 4

    Oncological Safety of Testosterone Replacement Therapy in Men With a History of Prostate Cancer: A Systematic Review.

    Alexandre Alves VA, Brasileiro Silva AA, Falcao Bisneto EL, et al.

    Cureus 2026; (18(3)):e104765 doi:10.7759/cureus.104765.

    PMID: 41943753
  5. 5

    Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.

    Bhasin S, Brito JP, Cunningham GR, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(5)):1715-1744 doi:10.1210/jc.2018-00229.

    PMID: 29562364
  6. 6

    Endocrine Disruptors and Prostate Cancer.

    Corti M, Lorenzetti S, Ubaldi A, et al.

    International journal of molecular sciences 2022; (23(3)) doi:10.3390/ijms23031216.

    PMID: 35163140
  7. 7

    Role of Androgen Receptor in Prostate Cancer: A Review.

    Fujita K, Nonomura N

    The world journal of men's health 2019; (37(3)):288-295 doi:10.5534/wjmh.180040.

    PMID: 30209899
  8. 8

    Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.

    Li Z, Bishop AC, Alyamani M, et al.

    Nature 2015; (523(7560)):347-51 doi:10.1038/nature14406.

    PMID: 26030522
  9. 9

    Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.

    Gupta S, Vanderbilt C, Abida W, et al.

    Prostate cancer and prostatic diseases 2020; (23(3)):507-516 doi:10.1038/s41391-020-0214-6.

    PMID: 32094488
  10. 10

    Testosterone Replacement Therapy in Men With Prostate Cancer on Active Surveillance: A Systematic Review of Oncological Safety.

    Aly M, Alshunaigat N, Habana Y, et al.

    Andrology 2026; doi:10.1111/andr.70313.

    PMID: 42446168
  11. 11

    Oncologic Outcomes of Testosterone Therapy for Men on Active Surveillance for Prostate Cancer: A Population-based Analysis.

    Kaplan-Marans E, Zhang TR, Hu JC

    European urology open science 2024; (60()):36-43 doi:10.1016/j.euros.2024.01.005.

    PMID: 38375342
  12. 12

    Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies.

    Santucci J, Stapleton P, Perera M, et al.

    BJU international 2025; (136(5)):788-799 doi:10.1111/bju.16870.

    PMID: 40747831
  13. 13

    Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease.

    Sarkar RR, Patel SH, Parsons JK, et al.

    Prostate cancer and prostatic diseases 2020; (23(4)):689-695 doi:10.1038/s41391-020-0241-3.

    PMID: 32513967
  14. 14

    Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.

    Corona G, Morgado LA, Capogrosso P, et al.

    Andrology 2026; doi:10.1111/andr.70285.

    PMID: 42334104
  15. 15

    Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.

    Pastuszak AW, Khanna A, Badhiwala N, et al.

    The Journal of urology 2015; (194(5)):1271-6.

    PMID: 26025500
  16. 16

    Clinical Oncological Tolerance of Testosterone Replacement Therapy Over Two Years Among Patients With High-Risk or Very High-Risk Prostate Cancer Undergoing Radiotherapy.

    Shigehara K, Naito R, Kawahara T, et al.

    Cureus 2025; (17(9)):e92806 doi:10.7759/cureus.92806.

    PMID: 41127766
  17. 17

    Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

    Schweizer MT, Antonarakis ES, Wang H, et al.

    Science translational medicine 2015; (7(269)):269ra2 doi:10.1126/scitranslmed.3010563.

    PMID: 25568070
  18. 18

    Testosterone Replacement Therapy in Prostate Cancer Survivors Treated With Radiation With and Without Androgen Deprivation Therapy: A Retrospective Study and Narrative Review.

    Chandra MS, Wang C, Gagliano-Jucá T, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(5)):679-688 doi:10.1016/j.eprac.2026.01.019.

    PMID: 41621657
  19. 19

    A systematic review and evidence-based analysis of ingredients in popular male testosterone and erectile dysfunction supplements.

    Kuchakulla M, Narasimman M, Soni Y, et al.

    International journal of impotence research 2021; (33(3)):311-317 doi:10.1038/s41443-020-0285-x.

    PMID: 32358510
  20. 20

    Effects of oral fenugreek-derived preparations on testosterone-related outcomes in adult men: a systematic review and meta-analysis of randomized placebo-controlled trials.

    Yang P, Niu Z, Guo J, et al.

    Frontiers in nutrition 2026; (13()):1903508 doi:10.3389/fnut.2026.1903508.

    PMID: 42688439
  21. 21

    Risk Associated with the Use of Selected Ingredients in Food Supplements.

    Jędrejko K, Lazur J, Muszyńska B

    Chemistry & biodiversity 2021; (18(2)):e2000686 doi:10.1002/cbdv.202000686.

    PMID: 33410585

This page is for informational purposes only and does not constitute medical advice about testosterone use or prostate cancer. Do not start TRT or an over-the-counter supplement without discussing it with your oncology team.